Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease
- PMID: 34757539
- DOI: 10.1007/s10719-021-10024-w
Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder that affects over 10 million aging people worldwide. This condition is characterized by the degeneration of dopaminergic neurons in the pars compacta region of the substantia nigra (SNpc) and by aggregation of proteins, commonly α-synuclein (SNCA). The formation of Lewy bodies that encapsulate aggregated proteins in lipid vesicles is a hallmark of PD. Glycosylation of proteins and neuroinflammation are involved in the pathogenesis. SNCA has many posttranslational modifications and interacts with components of membranes that affect aggregation. The large membrane lipid dolichol accumulates in the brain upon age and has a significant effect on membrane structure. The replacement of dopamine and dopaminergic neurons are at the forefront of therapeutic development. This review examines the role of membrane lipids, glycolipids, glycoproteins and dopamine in the aggregation of SNCA and development of PD. We discuss the SNCA-dopamine-neuromelanin-dolichol axis and the role of membranes in neuronal stem cells that could be a regenerative therapy for PD patients.
Keywords: Alpha-synuclein; Dolichol; Dopamine; Membrane lipids; Neuromelanin; Parkinson’s disease; Stem cells.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.Acta Neuropathol. 2019 Oct;138(4):575-595. doi: 10.1007/s00401-019-02023-x. Epub 2019 May 31. Acta Neuropathol. 2019. PMID: 31165254 Free PMC article.
-
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.J Clin Invest. 2014 Jul;124(7):3032-46. doi: 10.1172/JCI72176. Epub 2014 May 27. J Clin Invest. 2014. PMID: 24865427 Free PMC article.
-
Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.Mov Disord. 2023 Feb;38(2):256-266. doi: 10.1002/mds.29269. Epub 2022 Nov 9. Mov Disord. 2023. PMID: 36350188
-
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Free Radic Biol Med. 2013. PMID: 23743292 Review.
-
Neuronal vulnerability in Parkinson's disease.Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S52-4. doi: 10.1016/S1353-8020(11)70018-9. Parkinsonism Relat Disord. 2012. PMID: 22166454 Review.
Cited by
-
Protein profiling of extracellular vesicles from iPSC-derived astrocytes of patients with ALS/PDC in Kii peninsula.Neurol Sci. 2023 Dec;44(12):4511-4516. doi: 10.1007/s10072-023-07000-7. Epub 2023 Aug 24. Neurol Sci. 2023. PMID: 37615876
References
-
- Gai, W.P., Yuan, H.X., Li, X.Q., Power, J.T., Blumbergs, P.C., Jensen, P.H.: In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol. 166(2), 324–333 (2000) - PubMed
-
- Stefanis, L.: α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2(2), a009399 (2012)
-
- Videira, P.A.Q., Castro-Caldas, M.: Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. Front Neurosci. 12, 381 (2018). https://doi.org/10.3389/fnins.2018.00381 - DOI - PubMed - PMC
-
- Li, J., Uversky, V.N., Fink, A.L.: Conformational behavior of human alpha-synuclein is modulated by familial Parkinson’s disease point mutations A30P and A53T. Neurotoxicology 23(4–5), 553–567 (2002) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous